v3.25.1
Significant Transactions (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Jan. 29, 2025
USD ($)
shares
Feb. 25, 2024
USD ($)
Dec. 01, 2022
Sep. 16, 2022
USD ($)
shares
Nov. 01, 2021
USD ($)
$ / shares
shares
Aug. 23, 2021
USD ($)
shares
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2022
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2024
USD ($)
Sep. 16, 2022
Sep. 16, 2022
lease
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Proceeds from sale of intellectual property                     $ 1,000,000        
Indefinite-lived intangible assets             $ 5,003,000     $ 5,003,000     $ 5,003,000    
Accrued licensing fee payable             1,325,000     1,325,000     $ 2,028,000    
General and administrative expenses             $ 2,973,000 $ 2,722,000   $ 8,516,000 $ 9,230,000        
PD-1 Asset Purchase Agreement | Otsuka Pharmaceutical | Intellectual Property                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Proceeds from sale of intellectual property   $ 1,000,000                          
Potential contingent payments related to sale of intellectual property   $ 52,500,000                          
The Purchase and Sale Agreement | College Station Investors                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Purchase price for Ground Lease Property         $ 28,750,000                    
Proceeds from sale of building         28,000,000                    
Base rent expense         $ 151,450                    
Interest rate on lease (percentage of facility's market value)         6.50%                    
The Credit Agreement | Woodforest National Bank                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Principal amount borrowed         $ 22,375,000                    
The Warrant | Bryan Capital | iBio Common Stock                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Warrants, shares issued | shares         2,579                    
Exercise price per share of warrants | $ / shares         $ 665                    
Warrants issued and exercisable | shares         579                    
Value of exercisable warrants         $ 217,255                    
Collaboration, Option and License Agreement | RubrYc Therapeutics                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Collaboration and license agreement, agreement term           5 years                  
Collaboration and license agreement, royalty payment term           10 years                  
AstralBio Exclusive License Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Payment of upfront licensing fee $ 750,000                            
Aggregate potential milestone payments payable in licensing agreement $ 28,000,000                            
Equity ownership (ceiling) 19.90%                            
Notice period to cancel licensing agreement 45 days                            
Notice period to cancel licensing agreement (material breach of contract) 90 days                            
Indefinite-lived intangible assets $ 750,000                            
Number of shares issued per agreement | shares 246,087                            
Stock Purchase Agreement | RubrYc Therapeutics | Series A-2 Preferred Stock                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Shares purchased in transaction | shares           2,864,345                  
Value of shares purchased in transaction           $ 7,500,000                  
Asset Purchase Agreement | RubrYc Therapeutics                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Liability for contingent consideration       $ 5,000,000                      
Cash advances to RubrYc to support operations       484,000                      
Transaction costs       208,000                      
Impairment of investment in RubrYc                       $ 1,760,000      
Impairment of current prepaid expense                       288,000      
Impairment of noncurrent prepaid expense                       $ 864,000      
Number of equipment leases assumed in asset acquisition                           3 3
Financing lease liabilities assumed in acquisition       $ 814,000                      
Asset Purchase Agreement | RubrYc Therapeutics | iBio Common Stock                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Number of shares issued per agreement | shares       5,117                      
Fair value of shares issued in agreement       $ 1,000,000                      
Fair value of shares issued and subject to lockup period       $ 650,000                      
Separation Agreement and General Release | Mr. Thomas F. Isett, Former Chief Executive Officer                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Period of bi-monthly installments of current base salary     24 months                        
Period of bi-monthly installments of target bonus     24 months                        
General and administrative expenses                 $ 2,130,000